Science

Researcher interest in CBD has been growing over the last two decades and has accelerated in the last five years. The sector now has an encouraging volume of research and publications for an array of maladies it can help.

Total Proportion of Medical Cannabis Publication By Target

Clinical Trials

Research and understanding around CBD is growing as a result of extensive clinical trials taking place across a number of countries. More than 275 clinic trails including trials running across multiple countries.

There is evidence supporting cannabinoid efficacy in a number of therapeutic areas especially in pain management, cancer, mood disorders and spasticity.

Brains Involvement In Clinical Trials

As one of the world’s few registered GMP-grade natural CBD API’s, Brains Bio’s CBD API is in increasing demand and is currently being utilised in 15 clinical trials around the world, exploring the effects of CBD on treating epilepsy, psychosis, anxiety & depression and PTSD.

Manufacturing

Prati Donaduzzi | Brazil Phase III Clinical Trial with our CBD API
- Epilepsy

Scientific Partners

King’s College London | UK
Trigal Pharma | Austria COVID-19

Researchers & Academics

University of Sao Paulo | Brazil
- Anxiety

Pre-Clinical Trials

As one of the world’s few registered GMP-grade natural CBD API’s, Brains’ CBD API is incr

Power of Cannabinoids

How CBD API Works

Endocannabinoid System

The endocannabinoid system (ECS) has been implicated as an emerging target of therapeutic potential for a wide range of diseases.

Brains is the exclusive supplier of pharmaceutical-grade natural CBD API to Prati Donaduzzi, for their Phase III clinical trial on refractory epilepsy.

Jas Kalsi

An experienced Chartered Professional Accountant with over 30 years of experience in providing personal and corporate taxation, corporate restructuring, financing, public offering and human resources management services. Kalsi is the Chief Financial Officer for Brains Bioceutical Corp., a global manufacturer of naturally-sourced active pharmaceutical ingredients (APIs). In this role, Kalsi is responsible for overseeing and managing the fiscal health of the group, implementing best practices with respect to finance, accounting and internal controls, obtaining funding, providing recommendations on mergers and acquisitions and working collaboratively with the CEO and Board of Directors on strategy. In addition, Kalsi will be responsible to regulatory entities and authorities, including any security exchange commissions.

Kalsi was an audit partner at KPMG focusing on small, medium and large private, government sector and public audit clients. He was the Human Resource Manager in charge of recruiting, staff development and training, and a member of KPMG’s Professional Practice Group. Subsequent to KPMG, Kalsi was the Chief Financial Officer / Chief Executive Officer of a variety of private companies including 6.5 years with a pharmaceutical fulfillment provider and API developer.

Kalsi has a proven track record in hiring top-level senior executives, restructuring companies to minimize tax and maximize cash flows, raising financing and creating a cohesive culture.

Kalsi has a passion for wellness and has created several initiatives and partnered with several leading-edge individuals to help people create and enjoy the best versions of themselves. He sees the use cannabinoids as a major tool to facilitate one’s optimum lifestyle.

With the team and infrastructure in place, Brains Bioceutical has quickly become an industry leader in both the nutraceutical and pharmaceutical cannabinoid industries, with several clinical trials and academic studies underway evaluating the efficacy of cannabinoids to treat major diseases. Under Kalsi’s leadership, Brains Bioceutical has already established market dominance, as it is the only company in the world to sell bulk API commercially around the world, supporting both the pharmaceutical and wellness sectors. With ambitious plans to expand Brains Bioceutical into a global biotech company specializing in cannabinoid health and wellness solutions, Kalsi is pioneering a new frontier in medicinal and wellness solutions across the world.

Science

Researcher interest in CBD has been growing over the last two decades and has accelerated in the last five years. The sector now has an encouraging volume of research and publications for an array of maladies it can help.

Total Proportion of Medical Cannabis Publication By Target

Total Proportion of Medical Cannabis Publication By Target

Clinical Trials